Commentary
Video
Dr Foster on Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma After Transplant
Author(s):
Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.
Laahn Foster, MD, Division of Hematology-Oncology, University of Virginia, discusses an analysis of the phase 3 AURIGA study (NCT03901963), evaluating daratumumab (Darzalex) plus lenalidomide (Revlimid) vs lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma after transplant. These results were presented at the 2024 ASH Annual Meeting.
Related Videos
Related Content
